Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer

Fig. 2

Evaluation of radiological tumour response (rad-TR) after NET by comparison with pathological tumour response (path-TR) and prognostic biomarkers for NET. (A–B) Rad-TR was assessed by MRI (A) and USS (B) and evaluated by mRECIST 1.1 criteria. Path-TR was evaluated using a modified Miller and Payne grading scale. In the upper square, tumours presenting complete response by MRI (A) or USS (B), but partial response (G2-G3) by path-TR, are highlighted in red. (C, E and G) Analysis of Ki67 levels at surgery in tumours classified according to their path-TR (C) and rad-TR by MRI (E) or USS (G). (D, F and H) Contingency analyses of the association between modified PEPI (mPEPI) score and path-TR (D) and rad-TR by MRI (F) or USS (H). p values were calculated using Kruskal–Wallis test (A–C, E, G) or Chi-square test (D, F and H). CR: complete response, PR: partial response, SD: stable disease, and PD: progression disease

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us